MoonLake Immunotherapeutics
MLTX
$16.47
-$0.03-0.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.24% | 68.36% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.94% | 7.37% | |||
| Operating Income | 11.94% | -7.37% | |||
| Income Before Tax | 10.67% | -10.06% | |||
| Income Tax Expenses | -85.53% | 150.81% | |||
| Earnings from Continuing Operations | 11.34% | -10.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.34% | -11.66% | |||
| EBIT | 11.94% | -7.37% | |||
| EBITDA | 12.16% | -7.31% | |||
| EPS Basic | 14.50% | -6.48% | |||
| Normalized Basic EPS | 13.87% | -6.56% | |||
| EPS Diluted | 14.50% | -6.48% | |||
| Normalized Diluted EPS | 13.87% | -6.56% | |||
| Average Basic Shares Outstanding | 3.71% | 4.86% | |||
| Average Diluted Shares Outstanding | 3.71% | 4.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||